- Conditions
- Spinal Muscular Atrophy
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Bannockburn, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2473–2496
of 12,573
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
- Interventions
- Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Pembrolizumab, Autologous Tumor Infiltrating Lymphocytes LN-145, Aldesleukin
- Drug · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Fibromyalgia, CFS
- Interventions
- Smart Energy System
- Dietary Supplement
- Lead sponsor
- Practitioners Alliance Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Kailua, Hawaii
- Conditions
- Lung Cancer Metastatic, EGFR Gene Mutation
- Interventions
- Osimertinib, Alisertib
- Drug
- Lead sponsor
- Collin Blakely
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Various Advanced Cancer
- Interventions
- Nivolumab, Ipilimumab, Relatlimab, Daratumumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 14
- States / cities
- Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more
- Conditions
- Overweight, Obesity
- Interventions
- LY3457263, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Autism Spectrum Disorder, Autism
- Interventions
- Intensive Center-Based Pivotal Response Treatment (PRT-C)
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 2 Years to 3 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage III Melanoma, Stage IV Melanoma, Stage IV Renal Cell Cancer
- Interventions
- recombinant interferon alfa-2b, amifostine/azacitidine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cocaine Dependence
- Interventions
- Citalopram, Placebo
- Drug
- Lead sponsor
- Joy Schmitz
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Resectable Non-small Cell Lung Cancer
- Interventions
- Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Clermont, Florida • Chicago, Illinois • Westwood, Kansas + 5 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Panobinostat, Fludarabine, Cytarabine, Intrathecal Triples, Leucovorin
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 4 more
- Conditions
- Obesity
- Interventions
- CagriSema (Cagrilintide B + semaglutide I), Low Energy Diet
- Drug · Behavioral
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Baton Rouge, Louisiana
- Conditions
- Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage III Small Lymphocytic Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Ann Arbor Stage IV Small Lymphocytic Lymphoma
- Interventions
- Lenalidomide, Rituximab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Myeloma
- Interventions
- Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
- Biological · Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Neurofibromatosis Type 1, Sarcoma
- Interventions
- filgrastim, doxorubicin hydrochloride, etoposide, ifosfamide, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Santa Monica, California • Chicago, Illinois + 13 more
- Conditions
- Vitreoretinal Disease
- Interventions
- CONSTELLATION® 27-gauge Combined Surgical Pak, CONSTELLATION® 23-gauge Combined Surgical Pak, Vitrectomy surgery
- Device · Procedure
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- paclitaxel, carboplatin, gefitinib, radiation therapy, laboratory biomarker analysis
- Drug · Radiation · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier
- Interventions
- Observational study with patients who may be treated with various disease-modifying therapies
- Other
- Lead sponsor
- The Duchenne Registry
- Other
- Eligibility
- Not listed
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2072
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 7 more
- Conditions
- HIV Infections
- Interventions
- Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
- Drug
- Lead sponsor
- The Wistar Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Lucinactant for Inhalation, nCPAP alone
- Drug · Device
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- 29 Weeks to 34 Weeks
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 8 more
- Conditions
- C-Section, Pain Management
- Interventions
- Exparel + Bupivacaine, Bupivacaine
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 186 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more
- Conditions
- Cardiovascular Diseases
- Interventions
- Estradiol+MPA, Estradiol+Drospirenone
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Leucovorin calcium
- Drug
- Lead sponsor
- U.S. Bioscience
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- West Conshohocken, Pennsylvania
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Pomalidomide, Quality-of-Life Assessment, Questionnaire Administration, Selinexor, X-Ray Imaging, Computed Tomography, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota